US Edition
Experimental weight-loss drug shows mostly mild side effects in trials – UK Diabetes Inpatient Forum
Summary by ukdiabetesinpatientforum.org
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Experimental weight-loss drug shows mostly mild side effects in trials – UK Diabetes Inpatient Forum
Full data from two major Phase 3 trials of Novo Nordisk’s investigational weight-loss treatment show that most side effects were mild to moderate, with positive outcomes reported for weight reduction and blood sugar control. CagriSema, a once-weekly injection that combines the GLP-1 receptor agonist semaglutide (used in Wegovy) with cagrilintide, an amylin analogue that suppresses appetite, is being studied as a new treatment option for people l…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
